BACKGROUND: Stimulation of the P2X7 purinergic receptor (P2X7) in bacille Calmette-Guerin (BCG)-infected human macrophages with extracellular adenosine triphosphate (ATP) leads to pore formation and killing of mycobacteria. We examined the effect of polymorphisms in the P2X7 gene (P2X7) on the capacity of macrophages to kill mycobacteria. METHODS: Polymorphisms and mutations in P2X7 were identified by both DNA sequence analysis and determination of uptake of ethidium by time-resolved flow cytometry. Macrophages from affected subjects were infected with Mycobacterium bovis BCG. Apoptosis was determined by use of Annexin V staining, and BCG growth was determined by use of quantitative mycobacterial cultures. RESULTS: Three new mutations were identified. Macrophages from subjects heterozygous for a polymorphism in P2X7 had a 50% reduction in uptake of ethidium and a 75% reduction in the number of apoptotic cells, compared with macrophages from wild-type (wt) subjects, after stimulation with interferon (IFN)- gamma and ATP. Furthermore, after stimulation with IFN- gamma and ATP, there was a reduction in BCG growth of up to approximately 0.5 log10 in macrophages from single-heterozygous subjects, compared with a reduction of 1.0 log10 in macrophages from wt subjects. Interestingly, BCG-infected macrophages from compound-heterozygous subjects, for different combinations of polymorphisms in P2X7, had no uptake of ethidium, failed to undergo apoptosis, and were unable to kill mycobacteria after stimulation with IFN- gamma and ATP. CONCLUSIONS: Various polymorphisms in P2X7 abrogate IFN- gamma /ATP-induced killing of mycobacteria by human macrophages and, thus, may contribute to variability in susceptibility to mycobacterial infections.
BACKGROUND: Stimulation of the P2X7 purinergic receptor (P2X7) in bacille Calmette-Guerin (BCG)-infected human macrophages with extracellular adenosine triphosphate (ATP) leads to pore formation and killing of mycobacteria. We examined the effect of polymorphisms in the P2X7 gene (P2X7) on the capacity of macrophages to kill mycobacteria. METHODS: Polymorphisms and mutations in P2X7 were identified by both DNA sequence analysis and determination of uptake of ethidium by time-resolved flow cytometry. Macrophages from affected subjects were infected with Mycobacterium bovis BCG. Apoptosis was determined by use of Annexin V staining, and BCG growth was determined by use of quantitative mycobacterial cultures. RESULTS: Three new mutations were identified. Macrophages from subjects heterozygous for a polymorphism in P2X7 had a 50% reduction in uptake of ethidium and a 75% reduction in the number of apoptotic cells, compared with macrophages from wild-type (wt) subjects, after stimulation with interferon (IFN)- gamma and ATP. Furthermore, after stimulation with IFN- gamma and ATP, there was a reduction in BCG growth of up to approximately 0.5 log10 in macrophages from single-heterozygous subjects, compared with a reduction of 1.0 log10 in macrophages from wt subjects. Interestingly, BCG-infected macrophages from compound-heterozygous subjects, for different combinations of polymorphisms in P2X7, had no uptake of ethidium, failed to undergo apoptosis, and were unable to kill mycobacteria after stimulation with IFN- gamma and ATP. CONCLUSIONS: Various polymorphisms in P2X7 abrogate IFN- gamma /ATP-induced killing of mycobacteria by human macrophages and, thus, may contribute to variability in susceptibility to mycobacterial infections.
Authors: Niklas R Jørgensen; Lise B Husted; Kristen K Skarratt; Leanne Stokes; Charlotte L Tofteng; Torben Kvist; Jens-Erik B Jensen; Pia Eiken; Kim Brixen; Stephen Fuller; Rory Clifton-Bligh; Alison Gartland; Peter Schwarz; Bente L Langdahl; James S Wiley Journal: Eur J Hum Genet Date: 2012-01-25 Impact factor: 4.246
Authors: E Fonfria; W C Clay; D S Levy; J A Goodwin; S Roman; G D Smith; J P Condreay; A D Michel Journal: Br J Pharmacol Date: 2007-11-26 Impact factor: 8.739
Authors: Robson Coutinho-Silva; Cristiane Monteiro da Cruz; Pedro M Persechini; David M Ojcius Journal: Purinergic Signal Date: 2007-01-12 Impact factor: 3.765
Authors: Michael P Lees; Stephen J Fuller; Rima McLeod; Nicola R Boulter; Catherine M Miller; Alana M Zakrzewski; Ernest J Mui; William H Witola; Jessica J Coyne; Aubrey C Hargrave; Sarra E Jamieson; Jenefer M Blackwell; James S Wiley; Nicholas C Smith Journal: J Immunol Date: 2010-05-19 Impact factor: 5.422
Authors: Melanie R Power Coombs; Mirjam E Belderbos; Leighanne C Gallington; Louis Bont; Ofer Levy Journal: Expert Rev Anti Infect Ther Date: 2011-02 Impact factor: 5.091
Authors: Tobias Engel; Alba Jimenez-Pacheco; Maria Teresa Miras-Portugal; Miguel Diaz-Hernandez; David C Henshall Journal: Int J Physiol Pathophysiol Pharmacol Date: 2012-12-26